Petros Grivas(@PGrivasMDPhD) 's Twitter Profileg
Petros Grivas

@PGrivasMDPhD

Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine

ID:3379037548

linkhttps://www.seattlecca.org/physicians/petros-grivas calendar_today16-07-2015 16:21:53

17,9K Tweet

16,4K Takipçi

11,9K Takip Edilen

Follow People
Philippe spiess(@SpiessPhilippe) 's Twitter Profile Photo

The San Raffaele GU Oncology Symposium in Milan led by Professor Necchi is quickly becoming a major thinktank meeting of thought leaders, Here is one of the impactful deliverables to come from it. sciencedirect.com/science/articl…

account_circle
PeerView(@PeerView) 's Twitter Profile Photo

Get practical guidance on using ADCs in individualized care of patients with in an event featuring Petros Grivas, Tian Zhang, MD, MHS, & Evan Y. Yu, MD. Produced with our partner Bladder Cancer Advocacy Network. 6/1 at 6:30 PM CDT: bit.ly/2024ADCBladderT

account_circle
Vinay Mathew Thomas(@vinay_onc) 's Twitter Profile Photo

Just in European Urology Oncology: We present gene expression in denovo vs relapsed (metachronous) mHSPC 👉⬆️ inflammatory pathways in denovo vs. ⬆️ AR pathways in relapsed mHSPC Thanks to mentors Umang Swami Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer OncoAlert Link bit.ly/3UTX3nn

Just in @EurUrolOncol: We present gene expression in denovo vs relapsed (metachronous) mHSPC #ProstateCancer 👉⬆️ inflammatory pathways in denovo vs. ⬆️ AR pathways in relapsed mHSPC Thanks to mentors @umangtalking @neerajaiims @Huntsman_GU @OncoAlert Link bit.ly/3UTX3nn
account_circle
Emre Yekedüz(@yekeduz_emre) 's Twitter Profile Photo

📍Keynote-057 Cohort B (Phase-2)

📍Pembrolizumab monotherapy IV 200 mg/3 weeks up to 35 cycles

📍High-risk non-muscle-invasive bladder cancer (High grade Ta, any grade T1) without carcinoma in situ and unresponsive to BCG

➡️12-month disease-free survival was 43·5% (95% CI…

📍Keynote-057 Cohort B (Phase-2) 📍Pembrolizumab monotherapy IV 200 mg/3 weeks up to 35 cycles 📍High-risk non-muscle-invasive bladder cancer (High grade Ta, any grade T1) without carcinoma in situ and unresponsive to BCG ➡️12-month disease-free survival was 43·5% (95% CI…
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

🧬🧬🧬New research suggests that there are different rates of cancer around the world due to unknown factors in the environment.
🧬 A study on a type of kidney cancer found that the gene changes varied in different countries, indicating different causes.
🔴This shows the need…

🧬🧬🧬New research suggests that there are different rates of cancer around the world due to unknown factors in the environment. 🧬 A study on a type of kidney cancer found that the gene changes varied in different countries, indicating different causes. 🔴This shows the need…
account_circle
Petros Grivas(@PGrivasMDPhD) 's Twitter Profile Photo

3 fantastic candidates for “beacon of hope” Bladder Cancer Advocacy Network wonderful to see my great colleague & collaborator Jonathan L Wright as a candidate!Link to vote (you can vote daily till deadline):

bcan.org/vote-for-the-2…

Sarah P. Psutka MD MS UW Urology Daniel Lin Claire de la Calle Yaw Nyame Betsy Koehne

account_circle
Parminder singh(@Parminder1699) 's Twitter Profile Photo

Great visit with Peter Black learning about new clinical trial design in muscle invasive bladder cancer based on subtypes, and role of proteomics and nothing beats a morning bicycle ride in scottsdale Joshua Meeks Seth lerner Petros Grivas Mark Tyson

Great visit with Peter Black learning about new clinical trial design in muscle invasive bladder cancer based on subtypes, and role of proteomics and nothing beats a morning bicycle ride in scottsdale @JoshMeeks @SethlernerMD @PGrivasMDPhD @MarkTysonMD
account_circle
Dana-Farber Lank Center for Genitourinary Oncology(@DanaFarber_GU) 's Twitter Profile Photo

Pleased to host our Brigham and Women’s Radiation Oncology colleague Dr. Mutlay Sayan (@MutlaySayan) for this month's GU Seminar, covering management of localized prostate cancer and his recently-published research identifying which patients might benefit from whole-pelvic radiation therapy.

Pleased to host our @BrighamRadOnc colleague Dr. Mutlay Sayan (@MutlaySayan) for this month's GU Seminar, covering management of localized prostate cancer and his recently-published research identifying which patients might benefit from whole-pelvic radiation therapy.
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

A deserving hard working, team player ! Bravo Pedro C Barata, MD MSc FACP University Hospitals ! This is just the start —Kudos also to super mentor (and prior mentor of mine) JAGarciaMD for being a selfless mentor (though average soccer ⚽️ player like FabriceAndre)

account_circle
Vadim Koshkin MD(@koshkin85) 's Twitter Profile Photo

Pedro C Barata, MD MSc FACP Jason Brown University Hospitals JAGarciaMD Dr. Theodoros Teknos Prateek Mendiratta Angela Jia Case Comp Cancer Ctr Neeraj Agarwal, MD, FASCO Brian Rini, MD Kim Allman Petros Grivas Sumanta K. Pal, MD, FASCO Lee Ponsky Congratulations Pedro C Barata, MD MSc FACP on this amazing achievement! So proud of you my friend! You’ve traveled a long way to get to this point and so highly deserve this honor! It has been amazing to watch your career grow from almost the very beginning and there’s much more you’ll still do

account_circle